These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 10997996)
1. Some limitations in the detection of residual aneuploid cells with dna quantification on immunophenotyped cells by flow cytometry. Nowak R; Oelschlägel U; Heider T; Naumann R; Ehninger G Br J Haematol; 2000 Sep; 110(3):751-3. PubMed ID: 10997996 [No Abstract] [Full Text] [Related]
2. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy. Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044 [TBL] [Abstract][Full Text] [Related]
3. Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Nowak R; Oelschlaegel U; Schuler U; Zengler H; Hofmann R; Ehninger G; Andreeff M Cytometry; 1997 Feb; 30(1):47-53. PubMed ID: 9056742 [TBL] [Abstract][Full Text] [Related]
4. A novel and easy FxCycle™ violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Tembhare P; Badrinath Y; Ghogale S; Patkar N; Dhole N; Dalavi P; Kunder N; Kumar A; Gujral S; Subramanian PG Cytometry A; 2016 Mar; 89(3):281-91. PubMed ID: 26671309 [TBL] [Abstract][Full Text] [Related]
5. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease. Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351 [No Abstract] [Full Text] [Related]
6. Flow cytometric DNA-quantification of three-color immunophenotyped cells for subpopulation specific determination of aneuploidy and proliferation. Oelschlaegel U; Freund D; Range U; Ehninger G; Nowak R J Immunol Methods; 2001 Jul; 253(1-2):145-52. PubMed ID: 11384676 [TBL] [Abstract][Full Text] [Related]
7. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease. Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896 [TBL] [Abstract][Full Text] [Related]
8. Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Nowak R; Oelschlägel U; Hofmann R; Zengler H; Huhn R Leuk Res; 1994 Dec; 18(12):897-901. PubMed ID: 7527882 [TBL] [Abstract][Full Text] [Related]
9. DNA content of human myeloma cells. Lewensohn R; Tribukait B; Hansson J Eur J Cancer Clin Oncol; 1983 Jan; 19(1):59-63. PubMed ID: 6682777 [TBL] [Abstract][Full Text] [Related]
10. Novel type of clonally involved cytoplasmic immunoglobulin-negative cells in multiple myeloma: flow cytometric study. Shimazaki C; Gotoh H; Oku N; Ashihara E; Inaba T; Murakami S; Ura Y; Nakagawa M; Fujita N Acta Haematol; 1992; 88(2-3):86-91. PubMed ID: 1466204 [TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. Godwin CD; Zhou Y; Othus M; Asmuth MM; Shaw CM; Gardner KM; Wood BL; Walter RB; Estey EH Blood; 2021 Jan; 137(4):569-572. PubMed ID: 33507294 [No Abstract] [Full Text] [Related]
12. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814 [TBL] [Abstract][Full Text] [Related]
13. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry. Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180 [TBL] [Abstract][Full Text] [Related]
14. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Mohan M; Szabo A; Yarlagadda N; Gundarlapalli S; Thanendrarajan S; Kendrick S; Schinke C; Alapat D; Sawyer J; Tian E; Tricot G; van Rhee F; Zangari M Am J Hematol; 2021 Sep; 96(9):E341-E344. PubMed ID: 34050985 [No Abstract] [Full Text] [Related]
15. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia. Maloum K; Charlotte F; Divine M; Cazin B; Lesty C; Merle-Béral H; Haematologica; 2006 Jun; 91(6):860-1. PubMed ID: 16769593 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571 [TBL] [Abstract][Full Text] [Related]
17. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Almeida J; Orfao A; Ocqueteau M; Mateo G; Corral M; Caballero MD; Blade J; Moro MJ; Hernandez J; San Miguel JF Br J Haematol; 1999 Oct; 107(1):121-31. PubMed ID: 10520032 [TBL] [Abstract][Full Text] [Related]
18. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128 [No Abstract] [Full Text] [Related]
20. Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. Olteanu H Surg Pathol Clin; 2016 Mar; 9(1):101-16. PubMed ID: 26940271 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]